Citations

Clear

4847 citation(s) found for "Tu, Eric".

Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results
Biller, Beverly M. K. , Gilis‐Januszewska, Aleksandra , Doknić, Mirjana , Picó, Antonio , Fleseriu, Maria , Raverot, Gérald , Takahashi, Yutaka , Garcia, José M. , Silverstein, Julie M, Huang, Eric, Kang, Jennifer, Domrzalski, Laurie, Shu, Aimee D , Beckert, Michael, Yuen, Kevin C.J. , Pico, Antonio Miguel , Isidori, Andrea M , Takahashi, Yutaka , Garcia, Jose M , Bancos, Irina , Fukuoka, Hidenori , Komirenko, Allison S , Shu, Aimee D , Yuen, Kevin C J , Biller, Beverly M K , Gilis-Januszewska, Aleksandra , Doknic, Mirjana , Fleseriu, Maria , Silverstein, Julie M, Huang, Eric, Kang, Jennifer, Domrzalski, Laurie, Beckert, Michael

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 19, 2025 | Volume: 111 | Issue: 6 | Pages: 1640-1650

10.1210/clinem/dgaf680 | PMID 41420532 Get It

Abstract Context Adult growth hormone (GH) deficiency (GHD) is characterized by metabolic abnormalities caused by insufficient GH production. Lonapegsomatropin, a prodrug administered once weekly, was designed to provide sustained release of unmodified somatropin to reduce the burden of daily somatropin injections. Objective This work aimed to evaluate the efficacy and safety of lonapegsomatropin vs placebo as treatment for adults with GHD. Methods The foresiGHt trial was a multicenter, randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial (NCT04615273) conducted at 116 centers in North America, Europe, and Asia-Pacific. The trial randomly assigned and dosed 259 adults with GHD. Participants were randomly assigned 1:1:1 to receive once-weekly lonapegsomatropin, once-weekly placebo, or daily somatropin for 38 weeks. The primary efficacy end point was change from baseline in trunk percent fat at week 38. Secondary efficacy end points included change from baseline in trunk fat mass and total body lean mass. Results At week 38, lonapegsomatropin significantly reduced trunk percent fat (−1.68% vs +0.37%; least squares [LS] mean difference −2.04%; P < .001), increased total body lean mass (+1.60 kg vs −0.11 kg; LS mean difference 1.70 kg; P < .0001), and reduced trunk fat mass (−0.48 kg vs +0.22 kg; LS mean difference −0.70 kg; P = .0053) vs placebo. The safety and tolerability profile of lonapegsomatropin was comparable to somatropin. Conclusion The foresiGHt trial met its primary efficacy end point by demonstrating superiority of lonapegsomatropin vs placebo with similar safety and tolerability, supporting its potential as a once-weekly treatment option for adults with GHD.
Epigenomic study of the lower airway reveals COPD-associated methylation patterns and potential microbiota links
Cao, Sudan , Shrivastav, Abhishek, Bleecker, Eugene R., Madapoosi, Siddharth , Erb‐Downward, John R. , Zein, Joe , Howard, Timothy D. , Hawkins, Gregory A., Barjaktarević, Igor , Bowler, Russell, Barr, Robert, Comellas, Alejandro P. , Cooper, Christopher B. , Hansel, Nadia N. , Hastie, Annette T. , Kanner, Richard E. , Moore, Wendy C. , O’Neal, Wanda K. , Paine, Robert , Smith, Benjamin M. , Hoffman, Eric A. , Meyers, Deborah A. , Woodruff, Prescott G. , Christenson, Stephanie A. , Ortega, Victor E. , Cao, Shuo , Chen, Xianfeng , Barjaktarevic, Igor , Comellas, Alejandro P , Han, MeiLan King , Kim, Victor , Huang, Yvonne J , O'Neal, Wanda K , Hoffman, Eric A , Christenson, Stephanie A , Chen, Xianfeng, Couper, David , Kaner, Robert J. , Martínez, Fernando J. , Curtis, Jeffrey L.

Mayo Clinic

BMJ Open Respiratory Research | December 19, 2025 | Volume: 12 | Issue: 1 | Pages: e003572

10.1136/bmjresp-2025-003572 | PMID 41419234 Get It

Introduction Despite the identification of multiple susceptibility loci by genome-wide association studies (GWAS), considerable chronic obstructive pulmonary disease (COPD) heritability remains unexplained. Aim To identify interaction networks of airway epithelial cell DNA methylation in COPD and further explore potential correlations with airway bacterial composition, as potentially collective regulators of biological pathways influencing COPD severity. Methods Using DNA isolated from bronchial airway brushings of 67 ever-smokers (>20 pack-years) from the SubPopulations and InteRmediate Outcomes Measures in COPD Study (SPIROMICS), we assessed proportion of DNA methylation (β) by epigenome-wide association study (EWAS) and examined associations of differentially methylated CpG probes (DMPs) with risk for moderate-to-severe COPD (N=34) versus absent or mild COPD (N=33). We tested co-methylation modules generated by Weighted Correlation Network Analyses (WGCNA) for associations with moderate-to-severe COPD and with bacterial genus-level relative abundances (16S rRNA sequencing). Results EWAS-identified nominally significant DMPs enriched for lung function GWAS loci. Eigengenes in six WGCNA modules were associated with moderate-to-severe COPD (false discovery rate <0.05). Four of those modules were enriched for forced expiratory volume in 1 s/forced vital capacity GWAS loci, and five overlapped with DMPs from EWAS. Overlapping CpG loci in three COPD-associated modules were adjacent to mucin genes; one had 10 genes highly ranked by connectivity with MUC5B, including important pathway genes: B3GNT6 , DGKI and ITGA8 . CpGs in an independent COPD-associated module showed the most correlations with Rothia , with directionality suggestive of negative associations with moderate-severe COPD. Conclusions Bronchial epithelial DNA methylation modules enriched for lung function GWAS loci associate with COPD severity in SPIROMICS. Potential module relationships to bronchial bacterial composition require further validation.
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Pérez-Millan, Agnès , Falgàs, Neus , Borrego-Écija, Sergi, Antonell, Anna, Fernández-Villullas, Guadalupe, Esteller-Gauxax, Diana, Tort-Merino, Adrià, Bargalló, Núria, Balasa, Mircea, Lladó, Albert, Chrem, Patricio, Day, Gregory S. , Devenney, Emma , Huey, Edward D. , Ikeuchi, Takeshi, Jucker, Mathias, Roh, Jee Hoon , Vitali, Paolo , Ortíz, Ana Luisa Sosa, Llibre-Guerra, Jorge J, Gordon, Brian A., Sánchez-Valle, Raquel, (DIAN), The Dominantly Inherited Alzheimer Network, Daniels, Alisha , Courtney, Laura, Ziegemeier, Angela, Skrbec, Karina, Hellm, Cortaiga, Martin, Mariana , Ziegemeier, Ellen , Bartzel, Jamie, Xiong, Chengie , Xu, Xiong, Lu, Ruijin, Li, Yan , Nie, Yuzheng , Gremminger, Emily, Perrin, Richard J. , Franklin, Erin , Ibanez, Laura, Jerome, Gina, Stauber, Jennifer, Baker, Bryce, Minton, Matthew, Cruchaga, Carlos C, Goate, Alison M, Renton, Alan E, Picarello, Danielle M. , Benzinger, Tammie L S, Hornbeck, Russ C. , Chen, Allison, Chen, Charles D., Flores, Shaney, Joseph-Mathurin, Nelly, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Wang, Qing, Sabaredzovic, Edita, Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Vlassenko, Andrei G. , Wang, Yong, Hassenstab, Jason, Smith, Jennifer, Stout, Sarah, Marsh, Jacob, Morris, John C, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Graff-Radford, Neill R, Farlow, Martin R. , Chhatwal, Jasmeer P. , Maa, Courtney, Ishiguro, Takanobu , Ishii, Kenji, Senda, Michio, Salloway, Stephen , Bechara, Jacob A, Martins, Ralph, Fox, Nick C, Ryan, Natalie S. , Laske, Christoph , Timofejavaite, Reda, Kuder-Buletta, Elke, Graber-Sultan, Susanne, Obermueller, Ulrike, Xiong, Chengjie , Rödenbeck, Yvonne, Vӧglein, Jonathan, Méndez, Patricio Chrem, Vazquez, Silvia, Leon, Yudy Milena, Ramirez, Laura, Baena, Ana , Bocanegra, Yamile , Levey, Allan, Johnson, Erik C B, Seyfried, Nicholas T. , Ringman, John M. , Fagan, Anne M. , Mori, Hiroshi, Lopera, Francisco , Goate, Alison , Hassenstab, Jason , Borrego‐Écija, Sergi , Pérez‐Millan, Agnès , Ikeuchi, T , Vöglein, Jonathan , Roh, Jee Hoon , Vitali, Paolo , Gordon, Brian A , Bateman, Randall J , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Borrego-Écija, Sergi , Goate, Alison M , Bosch, Beatríz , Antonell, Anna, Fernández‐Villullas, Guadalupe , Esteller, Diana , Tort‐Merino, Adrià , Balasa, Mircea , Lladó, Albert , Aguillon, David , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Vöglein, Jonathan , Llibre‐Guerra, Jorge J. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sánchez‐Valle, Raquel , Supnet, Charlene , Lu, Ruijin, Wang, Guoqiao , Ibanez, Laura , Cruchaga, Carlos , Fulton‐Howard, Brian , Banks, Jessica N , Flores, Shaney , Goyal, Manu S. , Hobbs, Diana A. , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wang, Yong , Smith, Jennifer, Stout, Sarah H., Aschenbrenner, Andrew J. , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Berman, Sarah , Graff‐Radford, Neill R. , Senda, Michio , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Bechara, Jacob , Cash, David M. , Laske, Christoph , Fougère, Christian la , Reischl, Gerald , Lee, Jae Hong , Allegri, Ricardo , Surace, Ezequiel , Vazquez, Silvia, Ramírez, Laura, Serna, Laura, Johnson, Erik C. B. , Masters, Colin L. , Noble, James M. , Lopera, Francisco Javier

Mayo Clinic

Brain Communications | December 18, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaf488 | PMID 41523185 Get It

Abstract The cortical asymmetry index evaluates the cortical thickness asymmetry between hemispheres. We investigated cortical asymmetry index in asymptomatic and symptomatic mutation carriers of autosomal dominant Alzheimer’s disease to explore the brain asymmetry within the Alzheimer’s disease continuum. Sixty baseline T1-weighted MRI scans were obtained from the Clinic Barcelona cohort. Baseline and longitudinal MRI data from 564 participants within the dominantly inherited Alzheimer network observational study were used as an independent, confirmatory cohort. Cerebrospinal fluid and plasma neurofilament light chain levels were included when available. Cortical thickness was calculated using Freesurfer and cortical asymmetry index was calculated via an open-source pipeline. Cross-sectional analyses examined cortical asymmetry index differences based on clinical classification and APOE ε4 status, adjusting for age, sex and estimated years from onset, while correlations were assessed with age, estimated years from onset, mini-mental state examination scores, and neurofilament light. Longitudinal cortical asymmetry index evolution was modelled using generalized additive models in the dominantly inherited Alzheimer network observational study cohort, incorporating age, sex, and the interaction between group and estimated years from onset. The cortical asymmetry index successfully distinguished asymptomatic mutation carrier and symptomatic mutation carriers from healthy controls in the Clinic Barcelona cohort and symptomatic mutation carriers from controls in dominantly inherited Alzheimer network observational study. Higher cortical asymmetry index in mutation carriers (asymptomatic mutation carrier and symptomatic mutation carriers combined) and in symptomatic mutation carriers were associated with higher plasma neurofilament light levels, a closer proximity to symptom onset, and lower mini-mental state examination in the Clinic Barcelona cohort. In the dominantly inherited Alzheimer network observational study cohort, mutation carriers exhibited increased cortical asymmetry index compared to controls and correlated with elevated neurofilament light (plasma and Cerebrospinal fluid), lower mini-mental state examination, and a closer proximity to symptom onset. APOE3/3 carriers showed greater asymmetry than other APOE genotypes and significant cortical asymmetry index differences between asymptomatic mutation carrier and symptomatic mutation carriers. Longitudinally, cortical asymmetry index increased over time significantly in symptomatic mutation carriers. These findings underscore brain asymmetry as a potential biomarker for early Alzheimer’s disease progression in autosomal dominant Alzheimer’s disease, with implications for detection and monitoring tracking disease-related neuroanatomical changes.
Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial
Geva, Michal , Goldberg, Y. Paul, Leitner, Melanie , Cruz-Herranz, Andrés , Hand, Randal, Emek, Noga Gershoni, Tan, Andrew M. , Berry, James D. , Berry, James D , Shefner, Jeremy M. , Goldberg, Y. Paul, Chen, Kelly , Gershoni‐Emek, Noga, Paganoni, Sabrina , Macklin, Eric A. , Cudkowicz, Merit , Hayden, Michael R.

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | December 17, 2025 | Volume: 27 | Issue: 3-4 | Pages: 432-444

10.1080/21678421.2025.2597935 | PMID 41406304 Get It

Expanding the Molecular and Pathologic Spectrum of HSPB8 Myopathy and Distal Motor Neuropathy
Putko, Brendan , Sorenson, Eric J. , Niu, Zhiyv , Litchy, William J. , Mer, Georges , Milone, Margherita , Putko, Brendan Nicholas , Cui, Gaofeng , Liewluck, T , Niu, Zhiyv , Litchy, William J , Mer, Georges , Milone, M , Cui, Gaofeng , Liewluck, Teerin

Mayo Clinic

Neurology Genetics | December 16, 2025 | Volume: 12 | Issue: 1 | Pages: No page available

10.1212/nxg.0000000000200332 | PMID 41426051 Get It

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
Freeman, Ciara L. , Garcés, Juan-José, Lee, Holly , Papadimitriou, Marios , Silva, Ariosto Siqueira , Füller, Etta Rozen , Agius, Phaedra , Hansen, Doris K., Zhao, Xiaohong , Meads, Mark B. , Teer, Jamie K. , Hagner, Patrick R. , Alsina, Melissa , Ramasubramanian, Anusuya , Smith, Eric L. , Mailankody, Sham , Chesi, Marta, Hamadeh, Issam S. , Shain, Kenneth H. , Ilundain, Marta Larrayoz , Durante, Michael , Sharik, Meaghen E. , Du, Megan T. , Hagner, Patrick, Bergsagel, P. Leif , Landgren, C Ola , Maura, Francesco , Maclachlan, Kylee , Larráyoz, Marta , Ziccheddu, Bachisio , Meermeier, Erin W. , Garcés, Juan‐José , Durante, Michael , Firestone, Ross , Menges, Meghan A. , Reid, Kayla M. , Diamond, Benjamin , Sudalagunta, Praneeth Reddy , Leblay, Noémie , Ahn, Sungwoo , Fuller, Ethan, Briercheck, Edward L. , Hansen, Doris K. , Song, Xiaofei , Jelı́nek, Tomáš , Baz, Rachid , Smith, Eric, Giralt, Sergio , Bergsagel, P. Leif , Neri, Paola , Chesi, Marta , Martinez‐Climent, José A. , Locke, Frederick L. , Bahlis, Nizar Jacques , Landgren, Ola , Usmani, Saad Z.

Mayo Clinic

No container title available | December 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.08.692978 | PMID 41415462 Get It

ABSTRACT Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Slomovitz, Brian M. , Weroha, S. John , Chon, Hye Sook, Podder, Vivek , Markham, Merry Jennifer , Backes, Floor , Thomas, Eric D. , Tenney, Meaghan , Miller, David S. , Muller, Carolyn Y., Callahan, Michael J. , Liu, J. Rebecca, Teplinsky, Eleonora , Kamat, Aparna A., Chern, Jing‐Yi , Murphy, Martina, Choong, Grace M. , Moore, Elena Diaz, Alvarez, Edwin , Rodgers, William H. , Copeland, Larry J. , Herzog, Thomas J. , Podder, Vivek , Markham, Merry J , Backes, Floor , Tenney, Meaghan Elizabeth , Westin, Shannon N , Miller, David S , Edelson, Mitchell I , Teplinsky, Eleonora , Guy, Michael , Choong, Grace M , O'Malley, David M , Copeland, Larry J , Herzog, Thomas J , Coleman, Robert , Gershenson, David M , Deng, Wei, Chen, Lee-may , Edelson, Mitchell I. , Holman, Laura L. , Lea, Jayanthi Sivasothy , O’Malley, David M. , Coleman, Robert L. , Gershenson, David M.

Mayo Clinic

Journal of Clinical Oncology | December 12, 2025 | Volume: 44 | Issue: 3 | Pages: 153-163

10.1200/jco-25-01348 | PMID 41385758 Get It

PURPOSE Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)–p16–Rb pathway, features shared with hormone receptor–positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Wang, Yucai , Hwang, Steven R. , Villa, Diego , Kugathasan, Laveniya , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor , Hill, Brian T. , Bond, David A. , Maddocks, Kami J. , Nizamuddin, Imran , Danilov, Alexey V. , Argao, Christine, Ruan, Jia , Khan, Nazneen B., Ouchveridze, Evguenia, Mou, Eric , Pongas, Georgios , Lossos, Izidore S. , Harris, Zoey I., Young, Philip, Greenwell, Irl Brian , Gerber, Drew G. , Wang, Michael , Narkhede, Mayur , Stack, Anthony , Messmer, Marcus , Moyo, Tamara K. , Anna, Jacob, Stanisic, Alexander , Cohen, Jonathon B. , Hwang, Steven R , Villa, Diego , Kumar, Anita , Joseph, Ashlee , Brooks, Taylor R , Bond, David A , Kahl, Brad S , Ryan, Christine E , Grover, Natalie S , Tun, Aung M , Mou, Eric , Lossos, Izidore S , Moustafa, Muhamad Alhaj , Pophali, Priyanka , Gerber, Drew , Jain, Preetesh , Wang, Michael L , Narkhede, Mayur S , Mehta, Amitkumar , Stack, Anthony C , Bhansali, Rahul S , Barta, Stefan K , Ghosh, Nilanjan , Kamdar, Manali , Stanisic, Alexander V , Karmali, Reem , Maurer, Matthew , Cerhan, James R , Cohen, Jonathon B , Wang, Yucai , Larson, Melissa C. , Kahl, Brad S. , Ryan, Christine E. , Merryman, Reid W. , Grover, Natalie S. , Ouchveridze, Evguenia, Tun, Aung M. , Ayyappan, Sabarish Ram , Muñoz, Javier , Portell, Craig A. , Baidoun, Firas , Moustafa, Muhamad Alhaj , Reagan, Patrick Michael , Banaszak, Lauren Gabriele , Pophali, Priyanka A. , Velayati, Arash , Jain, Preetesh , Mehta, Amitkumar , Bhansali, Rahul S. , Kamdar, Manali , Anna, Jacob, Karmali, Reem , Maurer, Matthew J. , Cerhan, James R. , Martin, Peter

Mayo Clinic

Blood Advances | December 11, 2025 | Volume: 10 | Issue: 4 | Pages: 1372-1380

10.1182/bloodadvances.2025018527 | PMID 41380101 Get It

Abstract The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P&lt; .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P&lt; .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P&lt; .001]; median OS, 136.1 vs 75.3 months [P&lt; .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.
Organ Preservation for Nasal Cavity Cancers Using Definitive Radiotherapy for Avoiding Rhinectomy
Yang, Fan , Gui, Chengcheng , Wu, Yingzhi, Yu, Yao , McBride, Sean M. , Shamseddine, A. , Shim, Andy, Mah, Dennis , Dunn, Lara , Michel, Loren S. , Pfister, David G. , Sherman, Eric J. , Cracchiolo, Jennifer R. , Patel, Snehal G. , Cohen, Marc A. , Lee, Nancy Y. , Mankuzhy, Nikhil P. , Boe, Lillian A. , Riaz, Nadeem , Ganly, Ian , Wong, Richard J.

Mayo Clinic

JAMA Oncology | December 11, 2025 | Volume: 12 | Issue: 2 | Pages: 208

10.1001/jamaoncol.2025.5241 | PMID 41379436 Get It

This cohort study evaluates the use of definitive rhinectomy and adjuvant radiotherapy with or without chemotherapy for patients who declined rhinectomy or had unresectable disease.
Topical steroid withdrawal syndrome: developing diagnostic criteria through a modified Delphi method
Hsu, Cynhia, Guo, Lily, Adams, D. Daryl, Eichenfield, Lawrence F. , Friedman, Olivia Hsu, Serrao, Rocco, Sheary, Belinda , Sidbury, Robert , Yu, JiaDe , Davis, Dawn, Davis, Dawn Marie R. , Friedman, Olivia Hsu, Harris, Sarah, Shi, Vivian Y. , Simpson, Eric Lawrence , Lio, Peter

Mayo Clinic

British Journal of Dermatology | December 11, 2025 | Volume: 194 | Issue: 4 | Pages: 768-778

10.1093/bjd/ljaf518 | PMID 41379834 Get It

Abstract Background Topical steroid withdrawal syndrome (TSW) is an adverse event following discontinuation of topical corticosteroids (TCS) and is of growing interest among patients and dermatologists. The absence of well-defined diagnostic criteria and limited insights into the pathomechanisms make diagnosis and future research challenging. Objectives To propose preliminary diagnostic criteria for TSW with the erythemato-oedematous subtype applicable for adult and paediatric populations using a Delphi consensus approach informed by a thorough literature review that summarizes the signs, symptoms and histology of TSW. Methods Eleven clinicians experienced in diagnosing and treating suspected TSW in both children and adults participated in a three-round modified Delphi process. Two rounds of surveys were conducted, with items ranked using a 5-point Likert scale. A predefined consensus threshold of ≥ 75% was established for any one feature to be deemed important. The third round involved a live video conference where the panel reached a consensus on essential diagnostic criteria. Results The panel identified 18 critical diagnostic items, encompassing elements from the patient’s clinical history, signs and symptoms. This includes history of escalating TCS requirement, morphology and distribution differing from primary condition, regional or generalized spontaneous neuropathic pain and severe burning sensation of the skin. Conclusions Differentiating TSW from conditions such as severe atopic dermatitis remains challenging. By emphasizing the common signs and symptoms of TSW, we aim to encourage discussions among healthcare professionals and progress towards the development of a reliable diagnostic tool. An author video to accompany this article is available online.